Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Asymchem scoops up Snapdragon Chemistry

By Brian Buntz | February 12, 2022

Asymchem/SnapdragonThe CDMO Asymchem Laboratories (Tianjin, China) Co., Ltd. has entered into an agreement to acquire Snapdragon Chemistry, a US-based chemical technology company.

Asymchem will pay $57.94 million to acquire Snapdragon, which focuses on early-stage chemical process development services for the pharma and fine chemicals industries.

“We believe continuous flow manufacturing is a revolutionary technology and represents the future of pharmaceutical production, not only generating advantages to process safety and cost, but also bringing tremendous environmental benefits,” said Dr. Hao Hong, Chairman & CEO of Asymchem Group, in a statement.

Asymchem began working with Snapdragon in 2020 with a strategic investment that enabled the latter firm to bolster its cGMP drug substance manufacturing capacity.

Snapdragon was founded in 2014 as a spin-off of MIT and Boston University.

The company will operate as a standalone entity and continue its plans to increase the size of its manufacturing facility in Waltham, Massachusetts.

In December, Asymchem announced that it had listed its shares on the Hong Kong exchange under the stock code 002821.SZ/6821.HK.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

samsung biologics (1)
Samsung Biologics completes Bioepis spinoff to become pure-play pharma CDMO
Trelleborg grand opening of its Biopharma Center of Excellence in Northborough MA
Trelleborg opens expanded manufacturing facility in Massachusetts
This is the logo of Abbvie.
AbbVie invests $70M in U.S. biologics manufacturing, R&D expansion
Amgen
Amgen to invest $650M in Puerto Rico biologics facility
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE